Search - tctmd.com

Displaying 201 - 220 of 585

Sort: Relevancy | Date

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

TCTMD’s Top 10 Most Popular Stories for August 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2020

August 28, 2020

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

August 10, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

News Daily News

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

July 28, 2020

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

PCI or Not, Post-ACS Bleeding Is Tied to Mortality

News Daily News

PCI or Not, Post-ACS Bleeding Is Tied to Mortality

July 06, 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

News Conference News EuroPCR 2020

DynamX Bioadaptor Provides Promising Preliminary Results for De Novo Coronary Lesions

June 30, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

June 01, 2020

Drug-Coated Balloons for CAD: Some International Consensus

News

Drug-Coated Balloons for CAD: Some International Consensus

May 27, 2020

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

Like Tobacco, Long-term E-Cigarettes Harm Vascular Function

News Daily News

Like Tobacco, Long-term E-Cigarettes Harm Vascular Function

April 30, 2020

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.